Article

Transcription factor binding and individual genetic risk for valproate teratogenicity

2025-02-27

Abstract excerpt

Valproate (VPA) use during pregnancy is associated with a wide range of birth defects and adverse neurodevelopmental outcomes, but not all exposed children are affected and there is evidence for a genetic predisposition. We hypothesised that genomic variants that impact on the binding affinity of transcription factors (TFs) are integral to VPA-associated teratogenicity and a plausible explanation for variance in i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 80b7b343-4047-5bbf-9d1c-2c22e5e1a872
DOI: 10.1101/2025.02.24.25322812

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Transcription factor binding and individual genetic risk for valproate teratogenicityDOI 10.1101/2025.02.24.25322812Read

Transcription Factor Binding and Individual Genetic Risk of Valproate Teratogenicity.Semantic proximity Read

Integrative genomics reveals pathogenic mediator of valproate-induced neurodevelopmental disabilitySemantic proximity Read

Transgenerational adverse effects of valproate? A patient report from 90 affected familiesSemantic proximity Read

Sodium valproate rescues expression of <i>TRANK1</i> in iPSC-derived neural cells that carry a genetic variant associated with serious mental illnessSemantic proximity Read

Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual DisabilitySemantic proximity Read

Sodium valproate rescues expression of TRANK1 in iPSC-derived neural cells that carry a genetic variant associated with serious mental illness.Semantic proximity Read

A translational multimodal machine-learning prototype predicting valproate response in epilepsy treatmentSemantic proximity Read

Integrative analysis of noncoding mutations identifies the druggable genome in preterm birth.Semantic proximity Read

Risk of Adverse Pregnancy Outcomes Associated with Sodium Valproate(VPA): A Disproportionality Analysis Using the FDA Adverse Event Reporting System (FAERS)Semantic proximity Read

Assessing molecular gene by treatment interactions using a population of neural progenitors exposed to valproic acid and lithium.Semantic proximity Read

Antiseizure medication use during pregnancy and children’s neurodevelopmental outcomesSemantic proximity Read

Gestational valproate exposure induces tissue-specific transcriptomic changes in the neonatal brain and choroid plexus in a rat model of epilepsy, GAERSSemantic proximity Read